Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade
通过双重测序对接受阿扎胞苷维奈托克/免疫检查点阻断的老年急性髓系白血病患者的循环游离肿瘤 DNA 进行连续监测
基本信息
- 批准号:10337831
- 负责人:
- 金额:$ 10.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AML/MDSAcute Myelocytic LeukemiaAftercareAntibodiesArchitectureAutomobile DrivingBar CodesBiological MarkersBlood specimenBone MarrowCancer Therapy Evaluation ProgramCellsCharacteristicsClinicalClinical DataClonal EvolutionDNA sequencingDataDevelopmentDiseaseDisease remissionDrug usageFLT3 geneFutureGenerationsGenesImmunoglobulin Class SwitchingImmunophenotypingIn VitroInduced MutationIsocitrate DehydrogenaseLearningLeukemic CellMalignant neoplasm of ovaryMissionMulticenter TrialsMutateMutationNewly DiagnosedOligonucleotidesOutcomePatientsPatternPharmaceutical PreparationsPhenotypePoint MutationPopulationProcessProductionResistanceSamplingTechnologyTranslatingalternative treatmentbasechemotherapyclinical efficacyexperiencein vivoinhibitor/antagonistinsightinterestleukemiamalignant breast neoplasmmultiple omicsphase 2 studypredicting responsepreventresistance mechanismresponseresponse biomarkersingle cell sequencingsuccesstargeted agenttargeted treatmenttooltreatment responsetrend
项目摘要
ABSTRACT
IDH1 and IDH2 mutations are present in 15 to 20% of newly diagnosed cases of AML. They are
associated with the production of the onco-metabolite 2-Hydroxyglutarate and a distinctive clonal landscape. IDH
targeted inhibitors have been developed with success over the last decade but primary or secondary resistances
remain extremely common. Resistance is driven by a variety of mechanisms including isotype switch, IDH
secondary point mutation, acquisition of RTK mutation (such as RAS), or the development of IDH negative
clones. Identifying the mechanisms driving resistance in a patient is crucial to be able to develop strategies to
prevent and treat progressions. Our group has demonstrated that the presence IDH mutation induces a
“BRCAness phenotype” in cells and a sensitivity to PARP inhibitors. These in vitro and in vivo findings were
translated in a phase 2 study of Olaparib in IDH mutated AML and MDS (the PRIME study, CTEP #10264). For
patients treated with Olaparib, we expect to see a similar pattern of resistance mechanisms as the one seen with
IDH inhibitors and in order to optimize our therapies, we need to have a clear picture of the clonal complexity at
the different points of the treatment. Conventional “Bulk sequencing” can provide some information but the level of
granularity of the data may not be sufficient in all cases. Single cell sequencing may overcome these limitations
and the new generation of platforms, such as the Tapestri platform, allow integrated and reliable workflows that
can process a large volume of samples. More recently, multi-omics approaches have been developed with
concomitant immunophenotyping and this allows to refine even more the results by allowing to focus on different
cellular subsets.
In this proposal, we use Single Cell DNA Sequencing and multi-omics approach to evaluate the clonal
architecture before and during treatment with olaparib. Besides giving us more insights on the mode of action of
olaparib, this approach will help us define the mechanisms of primary and secondary resistance to olaparib in this
population. Consequently, this will guide our future strategies to overcome these resistances. Second, we will
correlate SCS data with clinical response and evaluate if SCS has the potential to be used as a biomarker of
response in a multicenter trial setting.
2
摘要
IDH1和IDH2突变存在于15%到20%的新诊断的AML病例中。他们是
与肿瘤代谢物2-羟基戊二酸的产生和独特的克隆景观有关。IDH
在过去的十年中,靶向抑制剂的开发取得了成功,但一次或二次抵抗
仍然非常普遍。抗性是由多种机制驱动的,包括同型开关,IDH
继发性点突变、获得RTK突变(如RAS)或发展为IDH阴性
克隆人。确定患者耐药的驱动机制对于制定治疗策略至关重要。
预防和治疗进展。我们的团队已经证明了IDH突变的存在会诱导
细胞中的“BRCAness表型”和对PARP抑制剂的敏感性。这些体外和体内的研究结果是
在IDH突变的急性髓系白血病和MDS中对奥拉帕利的第2阶段研究中翻译的(主要研究,CTEP#10264)。为
接受奥拉帕利治疗的患者,我们希望看到类似于使用奥拉帕利治疗的耐药机制的模式
IDH抑制剂,为了优化我们的治疗,我们需要对克隆的复杂性有一个清晰的了解
治疗的不同点。传统的“批量测序”可以提供一些信息,但
数据的粒度可能并不是在所有情况下都足够。单细胞测序可能会克服这些限制
新一代平台,如Tapestri平台,允许集成且可靠的工作流
可以处理大量的样品。最近,多种组学方法被开发出来,
随之而来的免疫表型鉴定,这允许通过专注于不同的
细胞子集。
在本方案中,我们使用单细胞DNA测序和多组学方法来评估克隆
奥拉帕利治疗前和治疗期间的结构。除了让我们更深入地了解
Olaparib,这一方法将有助于我们确定在本研究中对olaparib的原发和继发耐药机制
人口。因此,这将指导我们未来克服这些阻力的战略。第二,我们将
将SCS数据与临床反应相关联,并评估SCS是否有可能被用作
多中心试验环境中的反应。
2.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PATRICIA M. LORUSSO其他文献
PATRICIA M. LORUSSO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PATRICIA M. LORUSSO', 18)}}的其他基金
Supplement to UM1 grant for NCI's Early Therapeutics Clinical Trials Network (ETCTN)
NCI 早期治疗临床试验网络 (ETCTN) 的 UM1 补助金补充
- 批准号:
10678278 - 财政年份:2022
- 资助金额:
$ 10.83万 - 项目类别:
Integration of single cell sequencing as a biomarker of PARP inhibitor response for IDH1 and IDH2 mutated AML and MDS
整合单细胞测序作为 IDH1 和 IDH2 突变 AML 和 MDS 的 PARP 抑制剂反应的生物标志物
- 批准号:
10337798 - 财政年份:2021
- 资助金额:
$ 10.83万 - 项目类别:
Administrative Supplement for VICKtOrY Early Clinical Trials Consortium
VICKtory 早期临床试验联盟的行政补充
- 批准号:
10392078 - 财政年份:2021
- 资助金额:
$ 10.83万 - 项目类别:
ViKTriY Early Clinical Trials Consortium (ECTC)
ViKTriY 早期临床试验联盟 (ECTC)
- 批准号:
8725330 - 财政年份:2014
- 资助金额:
$ 10.83万 - 项目类别:
ViKTriY Early Clinical Trials Consortium (ECTC)
ViKTriY 早期临床试验联盟 (ECTC)
- 批准号:
8890125 - 财政年份:2014
- 资助金额:
$ 10.83万 - 项目类别:
Early Clinical Trials of New Anti-Cancer Agents
新型抗癌药物的早期临床试验
- 批准号:
7886178 - 财政年份:2009
- 资助金额:
$ 10.83万 - 项目类别:
Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
NCI研究的相关研究
- 批准号:
7761433 - 财政年份:2009
- 资助金额:
$ 10.83万 - 项目类别:
Correlative Studies for NCI Study #7977: Phase I trial of ABT-888 Plus Irinotecan
NCI研究的相关研究
- 批准号:
7525941 - 财政年份:2008
- 资助金额:
$ 10.83万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 10.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 10.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 10.83万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 10.83万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 10.83万 - 项目类别: